Navegando por Palavras-chave "Blepharitis"
Agora exibindo 1 - 3 de 3
Resultados por página
Opções de Ordenação
- ItemAcesso aberto (Open Access)Demodex folliculorum on the eyelash follicule of diabetic patients(Conselho Brasileiro de Oftalmologia, 2011-12-01) Yamashita, Letícia Satsiê Fátima de Freitas [UNIFESP]; Cariello, Angelino Julio [UNIFESP]; Geha, Nahin Mohamed Ali [UNIFESP]; Yu, Maria Cecilia Zorat [UNIFESP]; Hofling-Lima, Ana Luisa [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)PURPOSE: To compare the prevalence of Demodex folliculorum on the eyelashes of patients with proliferative diabetic retinopathy and healthy voluntaries. METHODS: Type 2 diabetic patients with proliferative retinopathy and age- and gender-matched healthy voluntaries (group control) underwent a slit lamp examination which three eyelashes containing cylindrical dandruff were removed from each lid by fine forceps. The lashes were dyed with fluorescein and the presence of Demodex folliculorum was verified by direct visualization under a light microscope. The mites were recognized based on its morphology and peculiar movement. The results were expressed in positive when at least one mite on one lash was found and negative when no mite was identified. The Chi-square test was used for comparing mites' presence in both groups. RESULTS: Forty-two patients were included in each group. The age ranged from 50 to 60 years old, with a mean of 56.4 ± 5.2 years. The male:female ratio was 0.6:1. There was no statistically significant difference with regard to age and gender in both groups (p>0.05). Demodex folliculorum was significantly more prevalent in diabetic patients (54.8%) than in control patients (38.1%) (p=0.048). CONCLUSION: Demodex folliculorum was more prevalent in diabetic patients than in healthy voluntaries, independently of gender and age.
- ItemSomente MetadadadosSafety and Efficacy of Moxifloxacin-Dexamethasone Eyedrops as Treatment for Bacterial Ocular Infection Associated with Bacterial Blepharitis(Springer, 2012-05-01) Belfort, Rubens [UNIFESP]; Gabriel, Luis [UNIFESP]; Martins Bispo, Paulo Jose [UNIFESP]; Muccioli, Cristina [UNIFESP]; Zacharias Serapicos, Patricia Cabral [UNIFESP]; Clark, Linda; Bell, Belinda; Bartell, John; Stroman, David W.; Hoefling-Lima, Ana Luisa [UNIFESP]; Universidade Federal de São Paulo (UNIFESP); Alcon Res LtdTreatments that offer two medications in a fixed combination have the potential to offer efficacious and safe treatment with advantages such as a regimen that is simpler than administering two separate solutions. This study evaluated the safety and efficacy of fixed-combination versus concomitant moxifloxacin 0.5% and dexamethasone 0.1% ocular solutions for the treatment of bacterial ocular inflammation and infection.The clinical study design was a randomized, double-masked, active-controlled, parallel-group trial of 102 subjects with bacterial blepharitis in which two patients also had bacterial conjunctivitis. All subjects received two bottles of study medication: either a fixed combination of moxifloxacin 0.5%/dexamethasone 0.1% ophthalmic solution and placebo eye drops (fixed-dose group), or moxifloxacin 0.5% ophthalmic solution and dexamethasone 0.1% (concomitant group). One drop of each study medication was instilled bilaterally four times per day for 7 days. Clinical resolution, signs, symptoms, and safety were assessed. Microbiological specimens were collected from the eyelid margin and conjunctivae of each eye from each patient at the time of enrollment and at the exit visit.Clinical resolution occurred similarly in both groups (81.6% of eyes, fixed-dose group; 82.3% of eyes, concomitant group). Moreover, the microbiological efficacy of the treatment was also similar for both the fixed-dose group (84%) and the concomitant group (83%). Ocular symptoms and signs improved over time, with no significant differences between groups after 7 days of treatment, except the fixed-dose group had significantly more eyes with clinical resolution in eyelid erythema (100%, n = 98/98, fixed-dose group; 92.7%, n = 89/96, concomitant group; P = 0.0194) and eyelid scaling/crusting (98%, n = 96/98, fixed-dose group; 89.6%; n = 86/96 eyes, concomitant group; P = 0.0337). Both regimens were safe and well tolerated.The fixed-dose combination of moxifloxacin, 0.5% and dexamethasone, 0.1% was therapeutically equivalent and as well tolerated as the concomitant dosage.
- ItemSomente MetadadadosTacrolimus Ointment for Refractory Posterior Blepharitis(Taylor & Francis Inc, 2017) Sakassegawa-Naves, Fernando Eiji; Moraes Ricci, Helena Maria; Moscovici, Bernardo Kaplan [UNIFESP]; Miyamoto, Daniela Akemi; Chiacchio, Brenda Biagio; Holzchuh, Ricardo; Santo, Ruth Muyuki; Hida, Richard YudiPurpose: This prospective, randomized, double-blind interventional case series was designed to evaluate the short-term efficacy of 0.03% tacrolimus ointment as a new therapeutic approach for refractory cases of posterior blepharitis.Methods: Forty eyes (20 patients) with posterior blepharitis refractory to previous treatment were randomized. Eighteen eyes (9 patients) were treated with 0.03% tacrolimus ointment and 20 eyes (10 patients) with placebo ointment twice daily. Patients were evaluated with a questionnaire and slit-lamp examination 14days and 28days after treatment, and symptoms and signs of blepharitis were compared to those observed at baseline.Results: We could observe statistical difference in the outcome measurements of meibomian gland secretion, conjunctival hyperemia, telangiectasia of inferior lid, Rose Bengal, and fluorescein scoring for the study group. As for the symptoms score, we observed statistical difference in the symptoms scoring for pruritus and dry eye sensation in the tacrolimus group.Conclusion: This study suggests that topical administration of 0.03% tacrolimus ointment can improve some symptoms and some ocular surface status in patients with refractory posterior blepharitis.